Growth Hormone Research
Tesamorelin
Growth hormone–releasing factor analog approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy — not a general weight-loss medicine.
EstablishedApproved medicine
View peptide →
Peptides in this group have been studied for their interaction with growth hormone–releasing hormone receptors, ghrelin receptors, or downstream GH/IGF-1 signaling. Approval status varies widely and should be read on each profile.
Growth Hormone Research
Growth hormone–releasing factor analog approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy — not a general weight-loss medicine.
View peptide →
Growth Hormone Research
Long-acting GHRH analog studied in healthy adults for prolonged GH and IGF-I secretion. Not an approved therapy for general use.
View peptide →
Growth Hormone Research
Selective ghrelin-receptor GH secretagogue characterized mainly in experimental models. Not an approved medicine.
View peptide →
Growth Hormone Research
GHRH (1-29) analog that was previously marketed in the U.S. Current routine availability and approved status should not be assumed from historical branding.
View peptide →
Growth Hormone Research
Ghrelin-receptor GH secretagogue used in some diagnostic and research contexts. Not established as an FDA-approved wellness therapy.
View peptide →
Growth Hormone Research
Older ghrelin-receptor GH secretagogue known experimentally to stimulate GH and, in some contexts, appetite. Not an approved medicine.
View peptide →